Biomarin Pharmaceutical Inc (OQ:BMRN)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 770 Lindaro Street
Tel: N/A
IR: See website
Key People
Alexander Hardy
President, Chief Executive Officer, Director
Brian R. Mueller
Chief Financial Officer, Executive Vice President - Finance
Henry J. Fuchs
President - Worldwide Research and Development
C. Greg Guyer
Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Jeffrey Robert Ajer
Executive Vice President, Chief Commercial Officer
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Erin Burkhart
Group Vice President, Chief Accounting Officer
Business Overview
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Financial Overview
For the three months ended 31 March 2024, Biomarin Pharmaceutical Inc revenues increased 9% to $648.8M. Net income increased 74% to $88.7M. Revenues reflect Voxzogo segment increase of 74% to $152.9M, Palynziq1 segment increase of 21% to $75.7M, Europe segment increase of 22% to $195.7M, United States segment increase of 16% to $193M. Net income benefited from Equity investment impairment decrease from $12.6M (expense) to $0K.
Employees: 3,401 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $14,672M as of Mar 31, 2024
Annual revenue (TTM): $2,472M as of Mar 31, 2024
EBITDA (TTM): $282.53M as of Mar 31, 2024
Net annual income (TTM): $205.46M as of Mar 31, 2024
Free cash flow (TTM): $163.21M as of Mar 31, 2024
Net Debt Last Fiscal Year: $41.38M as of Mar 31, 2024
Shares outstanding: 189,879,803 as of Apr 22, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.